{"chunk":"21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR Part 211 (July 24, 2025)\nThis content is from the eCFR and is authoritative but unofficial.\nTitle 21 \u2014Food and Drugs\nChapter I \u2014Food and Drug Administration, Department of Health and Human Services\nSubchapter C \u2014Drugs: General","book":"21_CFR_Part_211"}
{"chunk":"21 CFR Part 211 (July 24, 2025) (enhanced display) page 1 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals Part 211 Current Good Manufacturing Practice for Finished Pharmaceuticals\nSubpart A General Provisions\n\u00a7 211.1 Scope.\n\u00a7 211.3 Definitions.\nSubpart B Organization and Personnel","book":"21_CFR_Part_211"}
{"chunk":"\u00a7 211.22 Responsibilities of quality control unit.\n\u00a7 211.25 Personnel qualifications.\n\u00a7 211.28 Personnel responsibilities.\n\u00a7 211.34 Consultants.\nSubpart C Buildings and Facilities\n\u00a7 211.42 Design and construction features.\n\u00a7 211.44 Lighting.\n\u00a7 211.46 Ventilation, air filtration, air heating and cooling.\n\u00a7 211.48 Plumbing.","book":"21_CFR_Part_211"}
{"chunk":"\u00a7 211.48 Plumbing.\n\u00a7 211.50 Sewage and refuse.\n\u00a7 211.52 Washing and toilet facilities.\n\u00a7 211.56 Sanitation.\n\u00a7 211.58 Maintenance.\nSubpart D Equipment\n\u00a7 211.63 Equipment design, size, and location.\n\u00a7 211.65 Equipment construction.\n\u00a7 211.67 Equipment cleaning and maintenance.\n\u00a7 211.68 Automatic, mechanical, and electronic equipment.","book":"21_CFR_Part_211"}
{"chunk":"\u00a7 211.72 Filters.\nSubpart E Control of Components and Drug Product Containers and Closures\n\u00a7 211.80 General requirements.\n\u00a7 211.82 Receipt and storage of untested components, drug product containers, and closures.\n\u00a7 211.84 Testing and approval or rejection of components, drug product containers, and\nclosures.","book":"21_CFR_Part_211"}
{"chunk":"closures.\n\u00a7 211.86 Use of approved components, drug product containers, and closures.\n\u00a7 211.87 Retesting of approved components, drug product containers, and closures.\n\u00a7 211.89 Rejected components, drug product containers, and closures.\n\u00a7 211.94 Drug product containers and closures.\nSubpart F Production and Process Controls","book":"21_CFR_Part_211"}
{"chunk":"\u00a7 211.100 Written procedures; deviations.\n\u00a7 211.101 Charge-in of components.\n\u00a7 211.103 Calculation of yield.\n\u00a7 211.105 Equipment identification.\n\u00a7 211.110 21 CFR Part 211 (July 24, 2025) (enhanced display) 21 CFR Part 211 (July 24, 2025)\nSampling and testing of in-process materials and drug products.\npage 2 of 30","book":"21_CFR_Part_211"}
{"chunk":"page 2 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals \u00a7 211.111 Time limitations on production.\n\u00a7 211.113 Control of microbiological contamination.\n\u00a7 211.115 Reprocessing.\nSubpart G Packaging and Labeling Control\n\u00a7 211.122 Materials examination and usage criteria.","book":"21_CFR_Part_211"}
{"chunk":"\u00a7 211.125 Labeling issuance.\n\u00a7 211.130 Packaging and labeling operations.\n\u00a7 211.132 products.\n\u00a7 211.134 Drug product inspection.\n\u00a7 211.137 Expiration dating.\nSubpart H Holding and Distribution\n\u00a7 211.142 Warehousing procedures.\n\u00a7 211.150 Distribution procedures.\nSubpart I Laboratory Controls\n\u00a7 211.160 General requirements.","book":"21_CFR_Part_211"}
{"chunk":"\u00a7 211.165 Testing and release for distribution.\n\u00a7 211.166 Stability testing.\n\u00a7 211.167 Special testing requirements.\n\u00a7 211.170 Reserve samples.\n\u00a7 211.173 Laboratory animals.\n\u00a7 211.176 Penicillin contamination.\nSubpart J Records and Reports\n\u00a7 211.180 General requirements.\n\u00a7 211.182 Equipment cleaning and use log.","book":"21_CFR_Part_211"}
{"chunk":"\u00a7 211.184 Component, drug product container, closure, and labeling records.\n\u00a7 211.186 Master production and control records.\n\u00a7 211.188 Batch production and control records.\n\u00a7 211.192 Production record review.\n\u00a7 211.194 Laboratory records.\n\u00a7 211.196 Distribution records.\n\u00a7 211.198 Complaint files.\nSubpart K Returned and Salvaged Drug Products","book":"21_CFR_Part_211"}
{"chunk":"\u00a7 211.204 Returned drug products.\n\u00a7 211.208 Drug product salvaging.\n21 CFR Part 211 (July 24, 2025)\nTamper-evident packaging requirements for over-the-counter (OTC) human drug\n21 CFR Part 211 (July 24, 2025) (enhanced display) page 3 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)","book":"21_CFR_Part_211"}
{"chunk":"Current Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211\nPART 211\u2014CURRENT GOOD MANUFACTURING PRACTICE FOR\nFINISHED PHARMACEUTICALS\nAuthority: 21 U.S.C. 321,351,352,355,360b,371,374;42 U.S.C. 216,262,263a,264.\nLink to an amendment published at89 FR 51769, June 18, 2024.\nSource: 43 FR 45077, Sept. 29, 1978, unless otherwise noted.","book":"21_CFR_Part_211"}
{"chunk":"Subpart A\u2014General Provisions\n\u00a7 211.1 Scope.\nLink to an amendment published at89 FR 51769, June 18, 2024.\n(a) The regulations in this part contain the minimum current good manufacturing practice for preparation of\ndrug products (excluding positron emission tomography drugs) for administration to humans or animals.","book":"21_CFR_Part_211"}
{"chunk":"(b) The current good manufacturing practice regulations in this chapter as they pertain to drug products; in\nparts 600through680 of this chapter, as they pertain to drugs that are also biological products for human\nsupersede the more general.\n(c) Pending consideration of a proposed exemption, published in theFEDERAL REGISTERof September 29, 1978,","book":"21_CFR_Part_211"}
{"chunk":"the requirements in this part shall not be enforced for OTC drug products if the products and all their\ningredients are ordinarily marketed and consumed as human foods, and which products may also fall\nwithin the legal definition of drugs by virtue of their intended use. Therefore, until further notice,","book":"21_CFR_Part_211"}
{"chunk":"regulations underparts 110and117 of this chapter, and where applicable,parts 113through129 of this\nmanufactured, processed, packed, or held under current good manufacturing practice.\n[43 FR 45077, Sept. 29, 1978, as amended at 62 FR 66522, Dec. 19, 1997; 69 FR 29828, May 25, 2004; 74 FR 65431, Dec. 10, 2009;","book":"21_CFR_Part_211"}
{"chunk":"use; and inpart 1271 of this chapter, as they are applicable to drugs that are also human cells, tissues,\nand cellular and tissue-based products (HCT\/Ps) and that are drugs (subject to review under an\napplication submitted under section 505 of the act or under a biological product license application under","book":"21_CFR_Part_211"}
{"chunk":"section 351 of the Public Health Service Act); supplement and do not supersede the regulations in this\npart unless the regulations explicitly provide otherwise. In the event of a conflict between applicable\nregulations in this part and in other parts of this chapter, or inparts 600through680 of this chapter, or in","book":"21_CFR_Part_211"}
{"chunk":"part 1271 of this chapter, the regulation specifically applicable to the drug product in question shall\nchapter, shall be applied in determining whether these OTC drug products that are also foods are\n80 FR 56168, Sept. 17, 2015]\n\u00a7 211.3 Definitions.\nThe definitions set forth in\u00a7 210.3 of this chapterapply in this part.","book":"21_CFR_Part_211"}
{"chunk":"Subpart B\u2014Organization and Personnel\n21 CFR 211.3 (enhanced display) page 4 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.22\n\u00a7 211.22 Responsibilities of quality control unit.","book":"21_CFR_Part_211"}
{"chunk":"(a) There shall be a quality control unit that shall have the responsibility and authority to approve or reject all\ncomponents, drug product containers, closures, in-process materials, packaging material, labeling, and\ndrug products, and the authority to review production records to assure that no errors have occurred or, if","book":"21_CFR_Part_211"}
{"chunk":"errors have occurred, that they have been fully investigated. The quality control unit shall be responsible\nfor approving or rejecting drug products manufactured, processed, packed, or held under contract by\nanother company.\n(b) Adequate laboratory facilities for the testing and approval (or rejection) of components, drug product","book":"21_CFR_Part_211"}
{"chunk":"containers, closures, packaging materials, in-process materials, and drug products shall be available to\nthe quality control unit.\n(c) The quality control unit shall have the responsibility for approving or rejecting all procedures or\nspecifications impacting on the identity, strength, quality, and purity of the drug product.","book":"21_CFR_Part_211"}
{"chunk":"(d) The responsibilities and procedures applicable to the quality control unit shall be in writing; such written\nprocedures shall be followed.\n\u00a7 211.25 Personnel qualifications.\n(a) Each person engaged in the manufacture, processing, packing, or holding of a drug product shall have","book":"21_CFR_Part_211"}
{"chunk":"education, training, and experience, or any combination thereof, to enable that person to perform the\nassigned functions. Training shall be in the particular operations that the employee performs and in\ncurrent good manufacturing practice (including the current good manufacturing practice regulations in","book":"21_CFR_Part_211"}
{"chunk":"this chapter and written procedures required by these regulations) as they relate to the employee's\nfunctions. Training in current good manufacturing practice shall be conducted by qualified individuals on\na continuing basis and with sufficient frequency to assure that employees remain familiar with CGMP\nrequirements applicable to them.","book":"21_CFR_Part_211"}
{"chunk":"(b) Each person responsible for supervising the manufacture, processing, packing, or holding of a drug\nproduct shall have the education, training, and experience, or any combination thereof, to perform\nassigned functions in such a manner as to provide assurance that the drug product has the safety,","book":"21_CFR_Part_211"}
{"chunk":"identity, strength, quality, and purity that it purports or is represented to possess.\n(c) There shall be an adequate number of qualified personnel to perform and supervise the manufacture,\nprocessing, packing, or holding of each drug product.\n\u00a7 211.28 Personnel responsibilities.","book":"21_CFR_Part_211"}
{"chunk":"(a) Personnel engaged in the manufacture, processing, packing, or holding of a drug product shall wear clean\nclothing appropriate for the duties they perform. Protective apparel, such as head, face, hand, and arm\ncoverings, shall be worn as necessary to protect drug products from contamination.","book":"21_CFR_Part_211"}
{"chunk":"(b) Personnel shall practice good sanitation and health habits.\n(c) Only personnel authorized by supervisory personnel shall enter those areas of the buildings and facilities\ndesignated as limited-access areas.\n(d) Any person shown at any time (either by medical examination or supervisory observation) to have an","book":"21_CFR_Part_211"}
{"chunk":"apparent illness or open lesions that may adversely affect the safety or quality of drug products shall be\nexcluded from direct contact with components, drug product containers, closures, in-process materials,\n21 CFR 211.28(d) (enhanced display) page 5 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)","book":"21_CFR_Part_211"}
{"chunk":"Current Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.34\nand drug products until the condition is corrected or determined by competent medical personnel not to\njeopardize the safety or quality of drug products. All personnel shall be instructed to report to supervisory","book":"21_CFR_Part_211"}
{"chunk":"personnel any health conditions that may have an adverse effect on drug products.\n\u00a7 211.34 Consultants.\nConsultants advising on the manufacture, processing, packing, or holding of drug products shall have sufficient\neducation, training, and experience, or any combination thereof, to advise on the subject for which they are retained.","book":"21_CFR_Part_211"}
{"chunk":"Records shall be maintained stating the name, address, and qualifications of any consultants and the type of\nservice they provide.\nSubpart C\u2014Buildings and Facilities\n\u00a7 211.42 Design and construction features.\n(a) Any building or buildings used in the manufacture, processing, packing, or holding of a drug product shall","book":"21_CFR_Part_211"}
{"chunk":"be of suitable size, construction and location to facilitate cleaning, maintenance, and proper operations.\n(b) Any such building shall have adequate space for the orderly placement of equipment and materials to\nprevent mixups between different components, drug product containers, closures, labeling, in-process","book":"21_CFR_Part_211"}
{"chunk":"materials, or drug products, and to prevent contamination. The flow of components, drug product\ncontainers, closures, labeling, in-process materials, and drug products through the building or buildings\nshall be designed to prevent contamination.","book":"21_CFR_Part_211"}
{"chunk":"(c) Operations shall be performed within specifically defined areas of adequate size. There shall be separate\nor defined areas or such other control systems for the firm's operations as are necessary to prevent\ncontamination or mixups during the course of the following procedures:","book":"21_CFR_Part_211"}
{"chunk":"(1) Receipt, identification, storage, and withholding from use of components, drug product containers,\nclosures, and labeling, pending the appropriate sampling, testing, or examination by the quality\ncontrol unit before release for manufacturing or packaging;","book":"21_CFR_Part_211"}
{"chunk":"(2) Holding rejected components, drug product containers, closures, and labeling before disposition;\n(3) Storage of released components, drug product containers, closures, and labeling;\n(4) Storage of in-process materials;\n(5) Manufacturing and processing operations;\n(6) Packaging and labeling operations;","book":"21_CFR_Part_211"}
{"chunk":"(7) Quarantine storage before release of drug products;\n(8) Storage of drug products after release;\n(9) Control and laboratory operations;\n(10) Aseptic processing, which includes as appropriate:\n(i) Floors, walls, and ceilings of smooth, hard surfaces that are easily cleanable;\n(ii) Temperature and humidity controls;","book":"21_CFR_Part_211"}
{"chunk":"(iii) An air supply filtered through high-efficiency particulate air filters under positive pressure,\nregardless of whether flow is laminar or nonlaminar;\n21 CFR 211.42(c)(10)(iii) (enhanced display) page 6 of 30\n(d) 21 CFR Part 211 (up to date as of 7\/24\/2025)","book":"21_CFR_Part_211"}
{"chunk":"Current Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.42(c)(10)(iv)\n(iv) A system for monitoring environmental conditions;\n(v) A system for cleaning and disinfecting the room and equipment to produce aseptic conditions;\n(vi) A system for maintaining any equipment used to control the aseptic conditions.","book":"21_CFR_Part_211"}
{"chunk":"Operations relating to the manufacture, processing, and packing of penicillin shall be performed in\nfacilities separate from those used for other drug products for human use.\n[43 FR 45077, Sept. 29, 1978, as amended at 60 FR 4091, Jan. 20, 1995]\n\u00a7 211.44 Lighting.\nAdequate lighting shall be provided in all areas.","book":"21_CFR_Part_211"}
{"chunk":"\u00a7 211.46 Ventilation, air filtration, air heating and cooling.\n(a) Adequate ventilation shall be provided.\n(b) Equipment for adequate control over air pressure, micro-organisms, dust, humidity, and temperature shall\nbe provided when appropriate for the manufacture, processing, packing, or holding of a drug product.","book":"21_CFR_Part_211"}
{"chunk":"Air filtration systems, including prefilters and particulate matter air filters, shall be used when appropriate\non air supplies to production areas. If air is recirculated to production areas, measures shall be taken to\ncontrol recirculation of dust from production. In areas where air contamination occurs during production,","book":"21_CFR_Part_211"}
{"chunk":"there shall be adequate exhaust systems or other systems adequate to control contaminants.\nAir-handling systems for the manufacture, processing, and packing of penicillin shall be completely\nseparate from those for other drug products for human use.\n\u00a7 211.48 Plumbing.","book":"21_CFR_Part_211"}
{"chunk":"\u00a7 211.48 Plumbing.\n(a) Potable water shall be supplied under continuous positive pressure in a plumbing system free of defects\nthat could contribute contamination to any drug product. Potable water shall meet the standards\nprescribed in the Environmental Protection Agency's Primary Drinking Water Regulations set forth in40","book":"21_CFR_Part_211"}
{"chunk":"CFR part 141. Water not meeting such standards shall not be permitted in the potable water system.\n(c) (d) (b) Drains shall be of adequate size and, where connected directly to a sewer, shall be provided with an air\nbreak or other mechanical device to prevent back-siphonage.\n[43 FR 45077, Sept. 29, 1978, as amended at 48 FR 11426, Mar. 18, 1983]","book":"21_CFR_Part_211"}
{"chunk":"\u00a7 211.50 Sewage and refuse.\nSewage, trash, and other refuse in and from the building and immediate premises shall be disposed of in a safe and\nsanitary manner.\n\u00a7 211.52 Washing and toilet facilities.\nAdequate washing facilities shall be provided, including hot and cold water, soap or detergent, air driers or single-","book":"21_CFR_Part_211"}
{"chunk":"service towels, and clean toilet facilities easily accesible to working areas.\n21 CFR 211.52 (enhanced display) page 7 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.56\n\u00a7 211.56 Sanitation.","book":"21_CFR_Part_211"}
{"chunk":"(a) Any building used in the manufacture, processing, packing, or holding of a drug product shall be\nmaintained in a clean and sanitary condition, Any such building shall be free of infestation by rodents,\nbirds, insects, and other vermin (other than laboratory animals). Trash and organic waste matter shall be","book":"21_CFR_Part_211"}
{"chunk":"held and disposed of in a timely and sanitary manner.\n(b) There shall be written procedures assigning responsibility for sanitation and describing in sufficient detail\nthe cleaning schedules, methods, equipment, and materials to be used in cleaning the buildings and\nfacilities; such written procedures shall be followed.","book":"21_CFR_Part_211"}
{"chunk":"(c) There shall be written procedures for use of suitable rodenticides, insecticides, fungicides, fumigating\nagents, and cleaning and sanitizing agents. Such written procedures shall be designed to prevent the\ncontamination of equipment, components, drug product containers, closures, packaging, labeling","book":"21_CFR_Part_211"}
{"chunk":"materials, or drug products and shall be followed. Rodenticides, insecticides, and fungicides shall not be\nused unless registered and used in accordance with the Federal Insecticide, Fungicide, and Rodenticide\nAct (7 U.S.C. 135).\n(d) Sanitation procedures shall apply to work performed by contractors or temporary employees as well as","book":"21_CFR_Part_211"}
{"chunk":"work performed by full-time employees during the ordinary course of operations.\n\u00a7 211.58 Maintenance.\nAny building used in the manufacture, processing, packing, or holding of a drug product shall be maintained in a\ngood state of repair.\nSubpart D\u2014Equipment\n\u00a7 211.63 Equipment design, size, and location.","book":"21_CFR_Part_211"}
{"chunk":"Equipment used in the manufacture, processing, packing, or holding of a drug product shall be of appropriate\ndesign, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and\nmaintenance.\n\u00a7 211.65 Equipment construction.","book":"21_CFR_Part_211"}
{"chunk":"(a) Equipment shall be constructed so that surfaces that contact components, in-process materials, or drug\nproducts shall not be reactive, additive, or absorptive so as to alter the safety, identity, strength, quality, or\npurity of the drug product beyond the official or other established requirements.","book":"21_CFR_Part_211"}
{"chunk":"(b) Any substances required for operation, such as lubricants or coolants, shall not come into contact with\ncomponents, drug product containers, closures, in-process materials, or drug products so as to alter the\nsafety, identity, strength, quality, or purity of the drug product beyond the official or other established\nrequirements.","book":"21_CFR_Part_211"}
{"chunk":"requirements.\n\u00a7 211.67 Equipment cleaning and maintenance.\n(a) Equipment and utensils shall be cleaned, maintained, and, as appropriate for the nature of the drug,\nsanitized and\/or sterilized at appropriate intervals to prevent malfunctions or contamination that would","book":"21_CFR_Part_211"}
{"chunk":"alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other\nestablished requirements.\n21 CFR 211.67(a) (enhanced display) page 8 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.67(b)","book":"21_CFR_Part_211"}
{"chunk":"(b) Written procedures shall be established and followed for cleaning and maintenance of equipment,\nincluding utensils, used in the manufacture, processing, packing, or holding of a drug product. These\nprocedures shall include, but are not necessarily limited to, the following:","book":"21_CFR_Part_211"}
{"chunk":"(1) Assignment of responsibility for cleaning and maintaining equipment;\n(2) Maintenance and cleaning schedules, including, where appropriate, sanitizing schedules;\n(3) A description in sufficient detail of the methods, equipment, and materials used in cleaning and","book":"21_CFR_Part_211"}
{"chunk":"maintenance operations, and the methods of disassembling and reassembling equipment as\nnecessary to assure proper cleaning and maintenance;\n(4) Removal or obliteration of previous batch identification;\n(5) Protection of clean equipment from contamination prior to use;\n(6) Inspection of equipment for cleanliness immediately before use.","book":"21_CFR_Part_211"}
{"chunk":"(c) Records shall be kept of maintenance, cleaning, sanitizing, and inspection as specified in\u00a7\u00a7 211.180and\n211.182.\n[43 FR 45077, Sept. 29, 1978, as amended at 73 FR 51931, Sept. 8, 2008]\n\u00a7 211.68 Automatic, mechanical, and electronic equipment.","book":"21_CFR_Part_211"}
{"chunk":"(a) (b) (c) Automatic, mechanical, or electronic equipment or other types of equipment, including computers, or\nrelated systems that will perform a function satisfactorily, may be used in the manufacture, processing,\npacking, and holding of a drug product. If such equipment is so used, it shall be routinely calibrated,","book":"21_CFR_Part_211"}
{"chunk":"inspected, or checked according to a written program designed to assure proper performance. Written\nrecords of those calibration checks and inspections shall be maintained.\nAppropriate controls shall be exercised over computer or related systems to assure that changes in","book":"21_CFR_Part_211"}
{"chunk":"master production and control records or other records are instituted only by authorized personnel. Input\nto and output from the computer or related system of formulas or other records or data shall be checked\nfor accuracy. The degree and frequency of input\/output verification shall be based on the complexity and","book":"21_CFR_Part_211"}
{"chunk":"reliability of the computer or related system. A backup file of data entered into the computer or related\nsystem shall be maintained except where certain data, such as calculations performed in connection with\nlaboratory analysis, are eliminated by computerization or other automated processes. In such instances a","book":"21_CFR_Part_211"}
{"chunk":"written record of the program shall be maintained along with appropriate validation data. Hard copy or\nalternative systems, such as duplicates, tapes, or microfilm, designed to assure that backup data are\nexact and complete and that it is secure from alteration, inadvertent erasures, or loss shall be maintained.","book":"21_CFR_Part_211"}
{"chunk":"Such automated equipment used for performance of operations addressed by\u00a7\u00a7 211.101(c)or(d),\n211.103,211.182, or211.188(b)(11)can satisfy the requirements included in those sections relating to\nthe performance of an operation by one person and checking by another person if such equipment is","book":"21_CFR_Part_211"}
{"chunk":"used in conformity with this section, and one person checks that the equipment properly performed the\noperation.\n[43 FR 45077, Sept. 29, 1978, as amended at 60 FR 4091, Jan. 20, 1995; 73 FR 51932, Sept. 8, 2008]\n21 CFR 211.68(c) (enhanced display) page 9 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)","book":"21_CFR_Part_211"}
{"chunk":"Current Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.72\n\u00a7 211.72 Filters.\nFilters for liquid filtration used in the manufacture, processing, or packing of injectable drug products intended for\nhuman use shall not release fibers into such products. Fiber-releasing filters may be used when it is not possible to","book":"21_CFR_Part_211"}
{"chunk":"manufacture such products without the use of these filters. If use of a fiber-releasing filter is necessary, an\nadditional nonfiber-releasing filter having a maximum nominal pore size rating of 0.2 micron (0.45 micron if the\nmanufacturing conditions so dictate) shall subsequently be used to reduce the content of particles in the injectable","book":"21_CFR_Part_211"}
{"chunk":"drug product. The use of an asbestos-containing filter is prohibited.\n[73 FR 51932, Sept. 8, 2008]\nSubpart E\u2014Control of Components and Drug Product Containers and Closures\n\u00a7 211.80 General requirements.\n(a) There shall be written procedures describing in sufficient detail the receipt, identification, storage,","book":"21_CFR_Part_211"}
{"chunk":"handling, sampling, testing, and approval or rejection of components and drug product containers and\nclosures; such written procedures shall be followed.\n(b) Components and drug product containers and closures shall at all times be handled and stored in a\nmanner to prevent contamination.","book":"21_CFR_Part_211"}
{"chunk":"(c) Bagged or boxed components of drug product containers, or closures shall be stored off the floor and\nsuitably spaced to permit cleaning and inspection.\n(d) Each container or grouping of containers for components or drug product containers, or closures shall be","book":"21_CFR_Part_211"}
{"chunk":"identified with a distinctive code for each lot in each shipment received. This code shall be used in\nrecording the disposition of each lot. Each lot shall be appropriately identified as to its status (i.e.,\nquarantined, approved, or rejected).\n\u00a7 211.82 Receipt and storage of untested components, drug product containers, and closures.","book":"21_CFR_Part_211"}
{"chunk":"(a) Upon receipt and before acceptance, each container or grouping of containers of components, drug\nproduct containers, and closures shall be examined visually for appropriate labeling as to contents,\ncontainer damage or broken seals, and contamination.","book":"21_CFR_Part_211"}
{"chunk":"(b) Components, drug product containers, and closures shall be stored under quarantine until they have been\ntested or examined, whichever is appropriate, and released. Storage within the area shall conform to the\nrequirements of\u00a7 211.80.\n[43 FR 45077, Sept. 29, 1978, as amended at 73 FR 51932, Sept. 8, 2008]","book":"21_CFR_Part_211"}
{"chunk":"\u00a7 211.84 Testing and approval or rejection of components, drug product containers, and\nclosures.\n(a) Each lot of components, drug product containers, and closures shall be withheld from use until the lot has\nbeen sampled, tested, or examined, as appropriate, and released for use by the quality control unit.","book":"21_CFR_Part_211"}
{"chunk":"21 CFR 211.84(a) (enhanced display) page 10 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals (b) (c) (d) 21 CFR 211.84(b)\nRepresentative samples of each shipment of each lot shall be collected for testing or examination. The","book":"21_CFR_Part_211"}
{"chunk":"number of containers to be sampled, and the amount of material to be taken from each container, shall be\nbased upon appropriate criteria such as statistical criteria for component variability, confidence levels,\nand degree of precision desired, the past quality history of the supplier, and the quantity needed for","book":"21_CFR_Part_211"}
{"chunk":"analysis and reserve where required by\u00a7 211.170.\nSamples shall be collected in accordance with the following procedures:\n(1) The containers of components selected shall be cleaned when necessary in a manner to prevent\nintroduction of contaminants into the component.","book":"21_CFR_Part_211"}
{"chunk":"(2) The containers shall be opened, sampled, and resealed in a manner designed to prevent\ncontamination of their contents and contamination of other components, drug product containers, or\nclosures.\n(3) Sterile equipment and aseptic sampling techniques shall be used when necessary.","book":"21_CFR_Part_211"}
{"chunk":"(4) If it is necessary to sample a component from the top, middle, and bottom of its container, such\nsample subdivisions shall not be composited for testing.\n(5) Sample containers shall be identified so that the following information can be determined: name of","book":"21_CFR_Part_211"}
{"chunk":"the material sampled, the lot number, the container from which the sample was taken, the date on\nwhich the sample was taken, and the name of the person who collected the sample.\n(6) Containers from which samples have been taken shall be marked to show that samples have been\nremoved from them.\nSamples shall be examined and tested as follows:","book":"21_CFR_Part_211"}
{"chunk":"(1) At least one test shall be conducted to verify the identity of each component of a drug product.\nSpecific identity tests, if they exist, shall be used.\n(2) Each component shall be tested for conformity with all appropriate written specifications for purity,","book":"21_CFR_Part_211"}
{"chunk":"strength, and quality. In lieu of such testing by the manufacturer, a report of analysis may be\naccepted from the supplier of a component, provided that at least one specific identity test is\nconducted on such component by the manufacturer, and provided that the manufacturer establishes","book":"21_CFR_Part_211"}
{"chunk":"the reliability of the supplier's analyses through appropriate validation of the supplier's test results at\nappropriate intervals.\n(3) Containers and closures shall be tested for conformity with all appropriate written specifications. In\nlieu of such testing by the manufacturer, a certificate of testing may be accepted from the supplier,","book":"21_CFR_Part_211"}
{"chunk":"provided that at least a visual identification is conducted on such containers\/closures by the\nmanufacturer and provided that the manufacturer establishes the reliability of the supplier's test\nresults through appropriate validation of the supplier's test results at appropriate intervals.","book":"21_CFR_Part_211"}
{"chunk":"(4) When appropriate, components shall be microscopically examined.\n(5) Each lot of a component, drug product container, or closure that is liable to contamination with filth,\ninsect infestation, or other extraneous adulterant shall be examined against established\nspecifications for such contamination.","book":"21_CFR_Part_211"}
{"chunk":"(6) Each lot of a component, drug product container, or closure with potential for microbiological\ncontamination that is objectionable in view of its intended use shall be subjected to microbiological\ntests before use.\n21 CFR 211.84(d)(6) (enhanced display) page 11 of 30\n21 CFR 211.84(e)\n21 CFR Part 211 (up to date as of 7\/24\/2025)","book":"21_CFR_Part_211"}
{"chunk":"Current Good Manufacturing Practice for Finished Pharmaceuticals (e) Any lot of components, drug product containers, or closures that meets the appropriate written\nspecifications of identity, strength, quality, and purity and related tests underparagraph (d)of this section","book":"21_CFR_Part_211"}
{"chunk":"may be approved and released for use. Any lot of such material that does not meet such specifications\nshall be rejected.\n[43 FR 45077, Sept. 29, 1978, as amended at 63 FR 14356, Mar. 25, 1998; 73 FR 51932, Sept. 8, 2008]\n\u00a7 211.86 Use of approved components, drug product containers, and closures.","book":"21_CFR_Part_211"}
{"chunk":"Components, drug product containers, and closures approved for use shall be rotated so that the oldest approved\nstock is used first. Deviation from this requirement is permitted if such deviation is temporary and appropriate.\n\u00a7 211.87 Retesting of approved components, drug product containers, and closures.","book":"21_CFR_Part_211"}
{"chunk":"Components, drug product containers, and closures shall be retested or reexamined, as appropriate, for identity,\nstrength, quality, and purity and approved or rejected by the quality control unit in accordance with\u00a7 211.84as\nnecessary, e.g., after storage for long periods or after exposure to air, heat or other conditions that might adversely","book":"21_CFR_Part_211"}
{"chunk":"affect the component, drug product container, or closure.\n\u00a7 211.89 Rejected components, drug product containers, and closures.\nRejected components, drug product containers, and closures shall be identified and controlled under a quarantine\nsystem designed to prevent their use in manufacturing or processing operations for which they are unsuitable.","book":"21_CFR_Part_211"}
{"chunk":"\u00a7 211.94 Drug product containers and closures.\nLink to an amendment published at89 FR 51769, June 18, 2024.\n(a) Drug product containers and closures shall not be reactive, additive, or absorptive so as to alter the safety,\nidentity, strength, quality, or purity of the drug beyond the official or established requirements.","book":"21_CFR_Part_211"}
{"chunk":"Container closure systems shall provide adequate protection against foreseeable external factors in\nstorage and use that can cause deterioration or contamination of the drug product.\nDrug product containers and closures shall be clean and, where indicated by the nature of the drug,","book":"21_CFR_Part_211"}
{"chunk":"sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended\nuse. Such depyrogenation processes shall be validated.\nStandards or specifications, methods of testing, and, where indicated, methods of cleaning, sterilizing,","book":"21_CFR_Part_211"}
{"chunk":"and processing to remove pyrogenic properties shall be written and followed for drug product containers\nand closures.\nMedical gas containers and closures must meet the following requirements\u2014\n(1) Gas-specific use outlet connections.Portable cryogenic medical gas containers that are not","book":"21_CFR_Part_211"}
{"chunk":"manufactured with permanent gas use outlet connections (e.g., those that have been silver-brazed)\nmust have gas-specific use outlet connections that are attached to the valve body so that they\ncannot be readily removed or replaced (without making the valve inoperable and preventing the","book":"21_CFR_Part_211"}
{"chunk":"containers' use) except by the manufacturer. For the purposes of this paragraph, the term\n\u201cmanufacturer\u201d includes any individual or firm that fills high-pressure medical gas cylinders or\n21 CFR 211.94(e)(1) (enhanced display) (b) (c) (d) (e) page 12 of 30\n(2) 21 CFR Part 211 (up to date as of 7\/24\/2025)","book":"21_CFR_Part_211"}
{"chunk":"Current Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.94(e)(2)\ncryogenic medical gas containers. For the purposes of this section, a \u201cportable cryogenic medical\ngas container\u201d is one that is capable of being transported and is intended to be attached to a","book":"21_CFR_Part_211"}
{"chunk":"medical gas supply system within a hospital, health care entity, nursing home, other facility, or home\nhealth care setting, or is a base unit used to fill small cryogenic gas containers for use by individual\npatients. The term does not include cryogenic containers that are not designed to be connected to a","book":"21_CFR_Part_211"}
{"chunk":"medical gas supply system,e.g., tank trucks, trailers, rail cars, or small cryogenic gas containers for\nuse by individual patients (including portable liquid oxygen units as defined at\u00a7 868.5655 of this\nchapter).\nLabel and coloring requirements.The labeling specified at\u00a7 201.328(a) of this chaptermust be","book":"21_CFR_Part_211"}
{"chunk":"affixed to the container in a manner that does not interfere with other labeling and such that it is not\nsusceptible to becoming worn or inadvertently detached during normal use. Each such label as well\nas materials used for coloring medical gas containers must be reasonably resistant to fading,","book":"21_CFR_Part_211"}
{"chunk":"durable when exposed to atmospheric conditions, and not readily soluble in water.\n[43 FR 45077, Sept. 29, 1978, as amended at 73 FR 51932, Sept. 8, 2008; 81 FR 81697, Nov. 18, 2016]\nSubpart F\u2014Production and Process Controls\n\u00a7 211.100 Written procedures; deviations.","book":"21_CFR_Part_211"}
{"chunk":"(a) There shall be written procedures for production and process control designed to assure that the drug\nproducts have the identity, strength, quality, and purity they purport or are represented to possess. Such\nprocedures shall include all requirements in this subpart. These written procedures, including any","book":"21_CFR_Part_211"}
{"chunk":"changes, shall be drafted, reviewed, and approved by the appropriate organizational units and reviewed\nand approved by the quality control unit.\nWritten production and process control procedures shall be followed in the execution of the various\nproduction and process control functions and shall be documented at the time of performance. Any","book":"21_CFR_Part_211"}
{"chunk":"deviation from the written procedures shall be recorded and justified.\n\u00a7 211.101 Charge-in of components.\nWritten production and control procedures shall include the following, which are designed to assure that the drug\nproducts produced have the identity, strength, quality, and purity they purport or are represented to possess:","book":"21_CFR_Part_211"}
{"chunk":"(a) The batch shall be formulated with the intent to provide not less than 100 percent of the labeled or\nestablished amount of active ingredient.\nComponents for drug product manufacturing shall be weighed, measured, or subdivided as appropriate. If","book":"21_CFR_Part_211"}
{"chunk":"a component is removed from the original container to another, the new container shall be identified with\nthe following information:\n(1) Component name or item code;\n(2) Receiving or control number;\n(3) Weight or measure in new container;\n(4) Batch for which component was dispensed, including its product name, strength, and lot number.","book":"21_CFR_Part_211"}
{"chunk":"(b) (b) 21 CFR 211.101(b)(4) (enhanced display) page 13 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.101(c)\n(c) Weighing, measuring, or subdividing operations for components shall be adequately supervised. Each","book":"21_CFR_Part_211"}
{"chunk":"container of component dispensed to manufacturing shall be examined by a second person to assure\nthat:\n(1) The component was released by the quality control unit;\n(2) The weight or measure is correct as stated in the batch production records;\n(3) The containers are properly identified. If the weighing, measuring, or subdividing operations are","book":"21_CFR_Part_211"}
{"chunk":"performed by automated equipment under\u00a7 211.68, only one person is needed to assure\nparagraphs (c)(1),(c)(2), and(c)(3)of this section.\n(d) Each component shall either be added to the batch by one person and verified by a second person or, if\nthe components are added by automated equipment under\u00a7 211.68, only verified by one person.","book":"21_CFR_Part_211"}
{"chunk":"[43 FR 45077, Sept. 29, 1978, as amended at 73 FR 51932, Sept. 8, 2008]\n\u00a7 211.103 Calculation of yield.\nActual yields and percentages of theoretical yield shall be determined at the conclusion of each appropriate phase\nof manufacturing, processing, packaging, or holding of the drug product. Such calculations shall either be","book":"21_CFR_Part_211"}
{"chunk":"performed by one person and independently verified by a second person, or, if the yield is calculated by automated\nequipment under\u00a7 211.68, be independently verified by one person.\n(a) (b) [73 FR 51932, Sept. 8, 2008]\n\u00a7 211.105 Equipment identification.\nAll compounding and storage containers, processing lines, and major equipment used during the","book":"21_CFR_Part_211"}
{"chunk":"production of a batch of a drug product shall be properly identified at all times to indicate their contents\nand, when necessary, the phase of processing of the batch.\nMajor equipment shall be identified by a distinctive identification number or code that shall be recorded in","book":"21_CFR_Part_211"}
{"chunk":"the batch production record to show the specific equipment used in the manufacture of each batch of a\ndrug product. In cases where only one of a particular type of equipment exists in a manufacturing facility,\nthe name of the equipment may be used in lieu of a distinctive identification number or code.","book":"21_CFR_Part_211"}
{"chunk":"\u00a7 211.110 Sampling and testing of in-process materials and drug products.\n(a) To assure batch uniformity and integrity of drug products, written procedures shall be established and\nfollowed that describe the in-process controls, and tests, or examinations to be conducted on appropriate","book":"21_CFR_Part_211"}
{"chunk":"samples of in-process materials of each batch. Such control procedures shall be established to monitor\nthe output and to validate the performance of those manufacturing processes that may be responsible for\ncausing variability in the characteristics of in-process material and the drug product. Such control","book":"21_CFR_Part_211"}
{"chunk":"procedures shall include, but are not limited to, the following, where appropriate:\n(1) Tablet or capsule weight variation;\n(2) Disintegration time;\n(3) Adequacy of mixing to assure uniformity and homogeneity;\n(4) Dissolution time and rate;\n21 CFR 211.110(a)(4) (enhanced display) page 14 of 30","book":"21_CFR_Part_211"}
{"chunk":"(b) (c) (d) 21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.110(a)(5)\n(5) Clarity, completeness, or pH of solutions.\n(6) Bioburden testing.\nValid in-process specifications for such characteristics shall be consistent with drug product final","book":"21_CFR_Part_211"}
{"chunk":"specifications and shall be derived from previous acceptable process average and process variability\nestimates where possible and determined by the application of suitable statistical procedures where\nappropriate. Examination and testing of samples shall assure that the drug product and in-process\nmaterial conform to specifications.","book":"21_CFR_Part_211"}
{"chunk":"In-process materials shall be tested for identity, strength, quality, and purity as appropriate, and approved\nor rejected by the quality control unit, during the production process, e.g., at commencement or\ncompletion of significant phases or after storage for long periods.","book":"21_CFR_Part_211"}
{"chunk":"Rejected in-process materials shall be identified and controlled under a quarantine system designed to\nprevent their use in manufacturing or processing operations for which they are unsuitable.\n[43 FR 45077, Sept. 29, 1978, as amended at 73 FR 51932, Sept. 8, 2008]\n\u00a7 211.115 Reprocessing.","book":"21_CFR_Part_211"}
{"chunk":"(a) Written procedures shall be established and followed prescribing a system for reprocessing batches that\ndo not conform to standards or specifications and the steps to be taken to insure that the reprocessed\nbatches will conform with all established standards, specifications, and characteristics.","book":"21_CFR_Part_211"}
{"chunk":"(b) Reprocessing shall not be performed without the review and approval of the quality control unit.\nSubpart G\u2014Packaging and Labeling Control\n\u00a7 211.122 Materials examination and usage criteria.\n(a) There shall be written procedures describing in sufficient detail the receipt, identification, storage,","book":"21_CFR_Part_211"}
{"chunk":"handling, sampling, examination, and\/or testing of labeling and packaging materials; such written\nprocedures shall be followed. Labeling and packaging materials shall be representatively sampled, and\nexamined or tested upon receipt and before use in packaging or labeling of a drug product.\n21 CFR 211.122(a) (enhanced display) page 15 of 30","book":"21_CFR_Part_211"}
{"chunk":"\u00a7 211.111 Time limitations on production.\nWhen appropriate, time limits for the completion of each phase of production shall be established to assure the\nquality of the drug product. Deviation from established time limits may be acceptable if such deviation does not","book":"21_CFR_Part_211"}
{"chunk":"compromise the quality of the drug product. Such deviation shall be justified and documented.\n\u00a7 211.113 Control of microbiological contamination.\n(a) Appropriate written procedures, designed to prevent objectionable microorganisms in drug products not\nrequired to be sterile, shall be established and followed.","book":"21_CFR_Part_211"}
{"chunk":"(b) Appropriate written procedures, designed to prevent microbiological contamination of drug products\npurporting to be sterile, shall be established and followed. Such procedures shall include validation of all\naseptic and sterilization processes.\n[43 FR 45077, Sept. 29, 1978, as amended at 73 FR 51932, Sept. 8, 2008]","book":"21_CFR_Part_211"}
{"chunk":"(c) (d) (e) (f) (g) 21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.122(b)\n(b) Any labeling or packaging materials meeting appropriate written specifications may be approved and","book":"21_CFR_Part_211"}
{"chunk":"released for use. Any labeling or packaging materials that do not meet such specifications shall be\nrejected to prevent their use in operations for which they are unsuitable.\nRecords shall be maintained for each shipment received of each different labeling and packaging material","book":"21_CFR_Part_211"}
{"chunk":"indicating receipt, examination or testing, and whether accepted or rejected.\nLabels and other labeling materials for each different drug product, strength, dosage form, or quantity of\ncontents shall be stored separately with suitable identification. Access to the storage area shall be limited\nto authorized personnel.","book":"21_CFR_Part_211"}
{"chunk":"Obsolete and outdated labels, labeling, and other packaging materials shall be destroyed.\nUse of gang-printed labeling for different drug products, or different strengths or net contents of the same\ndrug product, is prohibited unless the labeling from gang-printed sheets is adequately differentiated by\nsize, shape, or color.","book":"21_CFR_Part_211"}
{"chunk":"If cut labeling is used for immediate container labels, individual unit cartons, or multiunit cartons\ncontaining immediate containers that are not packaged in individual unit cartons, packaging and labeling\noperations shall include one of the following special control procedures:","book":"21_CFR_Part_211"}
{"chunk":"(1) Dedication of labeling and packaging lines to each different strength of each different drug product;\n(2) Use of appropriate electronic or electromechanical equipment to conduct a 100-percent examination\nfor correct labeling during or after completion of finishing operations; or","book":"21_CFR_Part_211"}
{"chunk":"Use of visual inspection to conduct a 100-percent examination for correct labeling during or after\ncompletion of finishing operations for hand-applied labeling. Such examination shall be performed\nby one person and independently verified by a second person.","book":"21_CFR_Part_211"}
{"chunk":"Use of any automated technique, including differentiation by labeling size and shape, that physically\nprevents incorrect labeling from being processed by labeling and packaging equipment.\nPrinting devices on, or associated with, manufacturing lines used to imprint labeling upon the drug","book":"21_CFR_Part_211"}
{"chunk":"product unit label or case shall be monitored to assure that all imprinting conforms to the print specified\nin the batch production record.\n[43 FR 45077, Sept. 29, 1978, as amended at 58 FR 41353, Aug. 3, 1993; 77 FR 16163, Mar. 20, 2012]\n\u00a7 211.125 Labeling issuance.\nLink to an amendment published at89 FR 51769, June 18, 2024.","book":"21_CFR_Part_211"}
{"chunk":"(a) Strict control shall be exercised over labeling issued for use in drug product labeling operations.\n(b) Labeling materials issued for a batch shall be carefully examined for identity and conformity to the\nlabeling specified in the master or batch production records.","book":"21_CFR_Part_211"}
{"chunk":"Procedures shall be used to reconcile the quantities of labeling issued, used, and returned, and shall\nrequire evaluation of discrepancies found between the quantity of drug product finished and the quantity\nof labeling issued when such discrepancies are outside narrow preset limits based on historical operating","book":"21_CFR_Part_211"}
{"chunk":"data. Such discrepancies shall be investigated in accordance with\u00a7 211.192. Labeling reconciliation is\n(3) (4) (h) (c) 21 CFR 211.125(c) (enhanced display) page 16 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.125(d)","book":"21_CFR_Part_211"}
{"chunk":"waived for cut or roll labeling if a 100-percent examination for correct labeling is performed in accordance\nwith\u00a7 211.122(g)(2). Labeling reconciliation is also waived for 360\u00b0 wraparound labels on portable\n(d) (e) (f) cryogenic medical gas containers.\nAll excess labeling bearing lot or control numbers shall be destroyed.","book":"21_CFR_Part_211"}
{"chunk":"Returned labeling shall be maintained and stored in a manner to prevent mixups and provide proper\nidentification.\nProcedures shall be written describing in sufficient detail the control procedures employed for the\nissuance of labeling; such written procedures shall be followed.","book":"21_CFR_Part_211"}
{"chunk":"[43 FR 45077, Sept. 29, 1978, as amended at 58 FR 41354, Aug. 3, 1993; 81 FR 81697, Nov. 18, 2016]\n\u00a7 211.130 Packaging and labeling operations.\nThere shall be written procedures designed to assure that correct labels, labeling, and packaging materials are used","book":"21_CFR_Part_211"}
{"chunk":"for drug products; such written procedures shall be followed. These procedures shall incorporate the following\nfeatures:\n(a) (b) (c) (d) (e) Prevention of mixups and cross-contamination by physical or spatial separation from operations on other\ndrug products.","book":"21_CFR_Part_211"}
{"chunk":"drug products.\nIdentification and handling of filled drug product containers that are set aside and held in unlabeled\ncondition for future labeling operations to preclude mislabeling of individual containers, lots, or portions\nof lots. Identification need not be applied to each individual container but shall be sufficient to determine","book":"21_CFR_Part_211"}
{"chunk":"name, strength, quantity of contents, and lot or control number of each container.\nIdentification of the drug product with a lot or control number that permits determination of the history of\nthe manufacture and control of the batch.\nExamination of packaging and labeling materials for suitability and correctness before packaging","book":"21_CFR_Part_211"}
{"chunk":"operations, and documentation of such examination in the batch production record.\nInspection of the packaging and labeling facilities immediately before use to assure that all drug products\nhave been removed from previous operations. Inspection shall also be made to assure that packaging","book":"21_CFR_Part_211"}
{"chunk":"and labeling materials not suitable for subsequent operations have been removed. Results of inspection\nshall be documented in the batch production records.\n[43 FR 45077, Sept. 29, 1978, as amended at 58 FR 41354, Aug. 3, 1993]\n\u00a7 211.132 Tamper-evident packaging requirements for over-the-counter (OTC) human drug\nproducts.","book":"21_CFR_Part_211"}
{"chunk":"products.\nLink to an amendment published at89 FR 51769, June 18, 2024.\n(a) General.The Food and Drug Administration has the authority under the Federal Food, Drug, and Cosmetic\nAct (the act) to establish a uniform national requirement for tamper-evident packaging of OTC drug","book":"21_CFR_Part_211"}
{"chunk":"products that will improve the security of OTC drug packaging and help assure the safety and\neffectiveness of OTC drug products. An OTC drug product (except a dermatological, dentifrice, insulin, or\n21 CFR 211.132(a) (enhanced display) page 17 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)","book":"21_CFR_Part_211"}
{"chunk":"Current Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.132(b)\nlozenge product) for retail sale that is not packaged in a tamper-resistant package or that is not properly\nlabeled under this section is adulterated under section 501 of the act or misbranded under section 502 of\nthe act, or both.","book":"21_CFR_Part_211"}
{"chunk":"the act, or both.\n(b) Requirements for tamper-evident package.\n(1) Each manufacturer and packer who packages an OTC drug product (except a dermatological,\ndentifrice, insulin, or lozenge product) for retail sale shall package the product in a tamper-evident","book":"21_CFR_Part_211"}
{"chunk":"package, if this product is accessible to the public while held for sale. A tamper-evident package is\none having one or more indicators or barriers to entry which, if breached or missing, can reasonably\nbe expected to provide visible evidence to consumers that tampering has occurred. To reduce the","book":"21_CFR_Part_211"}
{"chunk":"likelihood of successful tampering and to increase the likelihood that consumers will discover if a\nproduct has been tampered with, the package is required to be distinctive by design or by the use of\none or more indicators or barriers to entry that employ an identifying characteristic (e.g., a pattern,","book":"21_CFR_Part_211"}
{"chunk":"name, registered trademark, logo, or picture). For purposes of this section, the term \u201cdistinctive by\ndesign\u201d means the packaging cannot be duplicated with commonly available materials or through\ncommonly available processes. A tamper-evident package may involve an immediate-container and","book":"21_CFR_Part_211"}
{"chunk":"closure system or secondary-container or carton system or any combination of systems intended to\nprovide a visual indication of package integrity. The tamper-evident feature shall be designed to and\nshall remain intact when handled in a reasonable manner during manufacture, distribution, and retail\ndisplay.","book":"21_CFR_Part_211"}
{"chunk":"display.\n(2) In addition to the tamper-evident packaging feature described inparagraph (b)(1)of this section, any\ntwo-piece, hard gelatin capsule covered by this section must be sealed using an acceptable tamper-\nevident technology.\n(c) Labeling.","book":"21_CFR_Part_211"}
{"chunk":"(c) Labeling.\n(1) In order to alert consumers to the specific tamper-evident feature(s) used, each retail package of an\nOTC drug product covered by this section (except ammonia inhalant in crushable glass ampules,\ncontainers of compressed medical oxygen, or aerosol products that depend upon the power of a","book":"21_CFR_Part_211"}
{"chunk":"liquefied or compressed gas to expel the contents from the container) is required to bear a\nstatement that:\n(i) Identifies all tamper-evident feature(s) and any capsule sealing technologies used to comply\nwithparagraph (b)of this section;\n(ii) Is prominently placed on the package; and","book":"21_CFR_Part_211"}
{"chunk":"(iii) Is so placed that it will be unaffected if the tamper-evident feature of the package is breached\nor missing.\n(2) If the tamper-evident feature chosen to meet the requirements inparagraph (b)of this section uses\nan identifying characteristic, that characteristic is required to be referred to in the labeling statement.","book":"21_CFR_Part_211"}
{"chunk":"For example, the labeling statement on a bottle with a shrink band could say \u201cFor your protection,\nthis bottle has an imprinted seal around the neck.\u201d\n(d) Request for exemptions from packaging and labeling requirements.A manufacturer or packer may request","book":"21_CFR_Part_211"}
{"chunk":"an exemption from the packaging and labeling requirements of this section. A request for an exemption is\nrequired to be submitted in the form of a citizen petition under\u00a7 10.30 of this chapterand should be\nclearly identified on the envelope as a \u201cRequest for Exemption from the Tamper-Evident Packaging Rule.\u201d","book":"21_CFR_Part_211"}
{"chunk":"The petition is required to contain the following:\n21 CFR 211.132(d) (enhanced display) page 18 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.132(d)(1)\n(1) The name of the drug product or, if the petition seeks an exemption for a drug class, the name of the","book":"21_CFR_Part_211"}
{"chunk":"drug class, and a list of products within that class.\n(2) The reasons that the drug product's compliance with the tamper-evident packaging or labeling\nrequirements of this section is unnecessary or cannot be achieved.\n(3) A description of alternative steps that are available, or that the petitioner has already taken, to reduce","book":"21_CFR_Part_211"}
{"chunk":"the likelihood that the product or drug class will be the subject of malicious adulteration.\n(4) Other information justifying an exemption.\n(e) OTC drug products subject to approved new drug applications.Holders of approved new drug applications\nfor OTC drug products are required under\u00a7 314.70 of this chapterto provide the agency with notification","book":"21_CFR_Part_211"}
{"chunk":"of changes in packaging and labeling to comply with the requirements of this section. Changes in\npackaging and labeling required by this regulation may be made before FDA approval, as provided under\u00a7\n314.70(c) of this chapter. Manufacturing changes by which capsules are to be sealed require prior FDA\napproval under\u00a7 314.70(b) of this chapter.","book":"21_CFR_Part_211"}
{"chunk":"(f) Poison Prevention Packaging Act of 1970.This section does not affect any requirements for \u201cspecial\npackaging\u201d as defined under\u00a7 310.3(l) of this chapterand required under the Poison Prevention\nPackaging Act of 1970.\n(Approved by the Office of Management and Budget under OMB control number 0910-0149)","book":"21_CFR_Part_211"}
{"chunk":"[54 FR 5228, Feb. 2, 1989, as amended at 63 FR 59470, Nov. 4, 1998]\n\u00a7 211.134 Drug product inspection.\n(a) Packaged and labeled products shall be examined during finishing operations to provide assurance that\ncontainers and packages in the lot have the correct label.","book":"21_CFR_Part_211"}
{"chunk":"(b) A representative sample of units shall be collected at the completion of finishing operations and shall be\nvisually examined for correct labeling.\n(c) Results of these examinations shall be recorded in the batch production or control records.\n\u00a7 211.137 Expiration dating.","book":"21_CFR_Part_211"}
{"chunk":"(a) To assure that a drug product meets applicable standards of identity, strength, quality, and purity at the\ntime of use, it shall bear an expiration date determined by appropriate stability testing described in\u00a7\n211.166.\n(b) (c) (d) (e) (f) Expiration dates shall be related to any storage conditions stated on the labeling, as determined by","book":"21_CFR_Part_211"}
{"chunk":"stability studies described in\u00a7 211.166.\nIf the drug product is to be reconstituted at the time of dispensing, its labeling shall bear expiration\ninformation for both the reconstituted and unreconstituted drug products.\nExpiration dates shall appear on labeling in accordance with the requirements of\u00a7 201.17 of this chapter.","book":"21_CFR_Part_211"}
{"chunk":"Homeopathic drug products shall be exempt from the requirements of this section.\nAllergenic extracts that are labeled \u201cNo U.S. Standard of Potency\u201d are exempt from the requirements of\nthis section.\n21 CFR 211.137(f) (enhanced display) page 19 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)","book":"21_CFR_Part_211"}
{"chunk":"Current Good Manufacturing Practice for Finished Pharmaceuticals (g) (h) 21 CFR 211.137(g)\nNew drug products for investigational use are exempt from the requirements of this section, provided that\nthey meet appropriate standards or specifications as demonstrated by stability studies during their use in","book":"21_CFR_Part_211"}
{"chunk":"clinical investigations. Where new drug products for investigational use are to be reconstituted at the time\nof dispensing, their labeling shall bear expiration information for the reconstituted drug product.\nPending consideration of a proposed exemption, published in theFEDERAL REGISTERof September 29, 1978,","book":"21_CFR_Part_211"}
{"chunk":"the requirements in this section shall not be enforced for human OTC drug products if their labeling does\nnot bear dosage limitations and they are stable for at least 3 years as supported by appropriate stability\ndata.\n[43 FR 45077, Sept. 29, 1978, as amended at 46 FR 56412, Nov. 17, 1981; 60 FR 4091, Jan. 20, 1995]","book":"21_CFR_Part_211"}
{"chunk":"Subpart H\u2014Holding and Distribution\n\u00a7 211.142 Warehousing procedures.\nWritten procedures describing the warehousing of drug products shall be established and followed. They shall\ninclude:\n(a) (b) Quarantine of drug products before release by the quality control unit.","book":"21_CFR_Part_211"}
{"chunk":"Storage of drug products under appropriate conditions of temperature, humidity, and light so that the\nidentity, strength, quality, and purity of the drug products are not affected.\n\u00a7 211.150 Distribution procedures.\nWritten procedures shall be established, and followed, describing the distribution of drug products. They shall\ninclude:","book":"21_CFR_Part_211"}
{"chunk":"include:\n(a) A procedure whereby the oldest approved stock of a drug product is distributed first. Deviation from this\nrequirement is permitted if such deviation is temporary and appropriate.\n(b) A system by which the distribution of each lot of drug product can be readily determined to facilitate its\nrecall if necessary.","book":"21_CFR_Part_211"}
{"chunk":"Subpart I\u2014Laboratory Controls\n\u00a7 211.160 General requirements.\n(a) The establishment of any specifications, standards, sampling plans, test procedures, or other laboratory\ncontrol mechanisms required by this subpart, including any change in such specifications, standards,","book":"21_CFR_Part_211"}
{"chunk":"sampling plans, test procedures, or other laboratory control mechanisms, shall be drafted by the\nappropriate organizational unit and reviewed and approved by the quality control unit. The requirements in\nthis subpart shall be followed and shall be documented at the time of performance. Any deviation from","book":"21_CFR_Part_211"}
{"chunk":"the written specifications, standards, sampling plans, test procedures, or other laboratory control\nmechanisms shall be recorded and justified.\n(b) Laboratory controls shall include the establishment of scientifically sound and appropriate specifications,","book":"21_CFR_Part_211"}
{"chunk":"standards, sampling plans, and test procedures designed to assure that components, drug product\ncontainers, closures, in-process materials, labeling, and drug products conform to appropriate standards\nof identity, strength, quality, and purity. Laboratory controls shall include:\n21 CFR 211.160(b) (enhanced display) page 20 of 30","book":"21_CFR_Part_211"}
{"chunk":"(2) (3) (4) 21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.160(b)(1)\n(1) Determination of conformity to applicable written specifications for the acceptance of each lot within\neach shipment of components, drug product containers, closures, and labeling used in the","book":"21_CFR_Part_211"}
{"chunk":"manufacture, processing, packing, or holding of drug products. The specifications shall include a\ndescription of the sampling and testing procedures used. Samples shall be representative and\nadequately identified. Such procedures shall also require appropriate retesting of any component,","book":"21_CFR_Part_211"}
{"chunk":"drug product container, or closure that is subject to deterioration.\nDetermination of conformance to written specifications and a description of sampling and testing\nprocedures for in-process materials. Such samples shall be representative and properly identified.","book":"21_CFR_Part_211"}
{"chunk":"Determination of conformance to written descriptions of sampling procedures and appropriate\nspecifications for drug products. Such samples shall be representative and properly identified.\nThe calibration of instruments, apparatus, gauges, and recording devices at suitable intervals in","book":"21_CFR_Part_211"}
{"chunk":"accordance with an established written program containing specific directions, schedules, limits for\naccuracy and precision, and provisions for remedial action in the event accuracy and\/or precision\nlimits are not met. Instruments, apparatus, gauges, and recording devices not meeting established\nspecifications shall not be used.","book":"21_CFR_Part_211"}
{"chunk":"[43 FR 45077, Sept. 29, 1978, as amended at 73 FR 51932, Sept. 8, 2008]\n\u00a7 211.165 Testing and release for distribution.\n(a) For each batch of drug product, there shall be appropriate laboratory determination of satisfactory\nconformance to final specifications for the drug product, including the identity and strength of each active","book":"21_CFR_Part_211"}
{"chunk":"ingredient, prior to release. Where sterility and\/or pyrogen testing are conducted on specific batches of\nshortlived radiopharmaceuticals, such batches may be released prior to completion of sterility and\/or\npyrogen testing, provided such testing is completed as soon as possible.","book":"21_CFR_Part_211"}
{"chunk":"There shall be appropriate laboratory testing, as necessary, of each batch of drug product required to be\nfree of objectionable microorganisms.\nAny sampling and testing plans shall be described in written procedures that shall include the method of\nsampling and the number of units per batch to be tested; such written procedure shall be followed.","book":"21_CFR_Part_211"}
{"chunk":"Acceptance criteria for the sampling and testing conducted by the quality control unit shall be adequate to\nassure that batches of drug products meet each appropriate specification and appropriate statistical\nquality control criteria as a condition for their approval and release. The statistical quality control criteria","book":"21_CFR_Part_211"}
{"chunk":"shall include appropriate acceptance levels and\/or appropriate rejection levels.\nThe accuracy, sensitivity, specificity, and reproducibility of test methods employed by the firm shall be\nestablished and documented. Such validation and documentation may be accomplished in accordance\nwith\u00a7 211.194(a)(2).","book":"21_CFR_Part_211"}
{"chunk":"(b) (c) (d) (e) (f) Drug products failing to meet established standards or specifications and any other relevant quality\ncontrol criteria shall be rejected. Reprocessing may be performed. Prior to acceptance and use,\nreprocessed material must meet appropriate standards, specifications, and any other relevant criteria.\n\u00a7 211.166 Stability testing.","book":"21_CFR_Part_211"}
{"chunk":"(a) There shall be a written testing program designed to assess the stability characteristics of drug products.\nThe results of such stability testing shall be used in determining appropriate storage conditions and\nexpiration dates. The written program shall be followed and shall include:\n21 CFR 211.166(a) (enhanced display) page 21 of 30","book":"21_CFR_Part_211"}
{"chunk":"(2) (3) (4) (5) (b) (c) 21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.166(a)(1)\n(1) Sample size and test intervals based on statistical criteria for each attribute examined to assure\nvalid estimates of stability;\nStorage conditions for samples retained for testing;","book":"21_CFR_Part_211"}
{"chunk":"Reliable, meaningful, and specific test methods;\nTesting of the drug product in the same container-closure system as that in which the drug product\nis marketed;\nTesting of drug products for reconstitution at the time of dispensing (as directed in the labeling) as\nwell as after they are reconstituted.","book":"21_CFR_Part_211"}
{"chunk":"An adequate number of batches of each drug product shall be tested to determine an appropriate\nexpiration date and a record of such data shall be maintained. Accelerated studies, combined with basic\nstability information on the components, drug products, and container-closure system, may be used to","book":"21_CFR_Part_211"}
{"chunk":"support tentative expiration dates provided full shelf life studies are not available and are being\nconducted. Where data from accelerated studies are used to project a tentative expiration date that is\nbeyond a date supported by actual shelf life studies, there must be stability studies conducted, including","book":"21_CFR_Part_211"}
{"chunk":"drug product testing at appropriate intervals, until the tentative expiration date is verified or the\nappropriate expiration date determined.\nFor homeopathic drug products, the requirements of this section are as follows:\n(1) There shall be a written assessment of stability based at least on testing or examination of the drug","book":"21_CFR_Part_211"}
{"chunk":"product for compatibility of the ingredients, and based on marketing experience with the drug\nproduct to indicate that there is no degradation of the product for the normal or expected period of\nuse.\nEvaluation of stability shall be based on the same container-closure system in which the drug\nproduct is being marketed.","book":"21_CFR_Part_211"}
{"chunk":"Allergenic extracts that are labeled \u201cNo U.S. Standard of Potency\u201d are exempt from the requirements of\nthis section.\n[43 FR 45077, Sept. 29, 1978, as amended at 46 FR 56412, Nov. 17, 1981]\n\u00a7 211.167 Special testing requirements.\nFor each batch of drug product purporting to be sterile and\/or pyrogen-free, there shall be appropriate","book":"21_CFR_Part_211"}
{"chunk":"laboratory testing to determine conformance to such requirements. The test procedures shall be in\nwriting and shall be followed.\nFor each batch of ophthalmic ointment, there shall be appropriate testing to determine conformance to\nspecifications regarding the presence of foreign particles and harsh or abrasive substances. The test","book":"21_CFR_Part_211"}
{"chunk":"procedures shall be in writing and shall be followed.\nFor each batch of controlled-release dosage form, there shall be appropriate laboratory testing to\ndetermine conformance to the specifications for the rate of release of each active ingredient. The test\nprocedures shall be in writing and shall be followed.\n\u00a7 211.170 Reserve samples.","book":"21_CFR_Part_211"}
{"chunk":"(2) (d) (a) (b) (c) 21 CFR 211.170 (enhanced display) page 22 of 30\n21 CFR 211.170(a)\n(2) (ii) (3) (b) 21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals Link to an amendment published at89 FR 51770, June 18, 2024.","book":"21_CFR_Part_211"}
{"chunk":"(a) An appropriately identified reserve sample that is representative of each lot in each shipment of each\nactive ingredient shall be retained. The reserve sample consists of at least twice the quantity necessary\nfor all tests required to determine whether the active ingredient meets its established specifications,","book":"21_CFR_Part_211"}
{"chunk":"except for sterility and pyrogen testing. The retention time is as follows:\n(1) For an active ingredient in a drug product other than those described inparagraphs (a) (2)and(3)of\nthis section, the reserve sample shall be retained for 1 year after the expiration date of the last lot of\nthe drug product containing the active ingredient.","book":"21_CFR_Part_211"}
{"chunk":"For an active ingredient in a radioactive drug product, except for nonradioactive reagent kits, the\nreserve sample shall be retained for:\n(i) Three months after the expiration date of the last lot of the drug product containing the active\ningredient if the expiration dating period of the drug product is 30 days or less; or","book":"21_CFR_Part_211"}
{"chunk":"Six months after the expiration date of the last lot of the drug product containing the active\ningredient if the expiration dating period of the drug product is more than 30 days.\nFor an active ingredient in an OTC drug product that is exempt from bearing an expiration date under","book":"21_CFR_Part_211"}
{"chunk":"\u00a7 211.137, the reserve sample shall be retained for 3 years after distribution of the last lot of the\ndrug product containing the active ingredient.\nAn appropriately identified reserve sample that is representative of each lot or batch of drug product shall","book":"21_CFR_Part_211"}
{"chunk":"be retained and stored under conditions consistent with product labeling. The reserve sample shall be\nstored in the same immediate container-closure system in which the drug product is marketed or in one\nthat has essentially the same characteristics. The reserve sample consists of at least twice the quantity","book":"21_CFR_Part_211"}
{"chunk":"necessary to perform all the required tests, except those for sterility and pyrogens. Except for those for\ndrug products described inparagraph (b)(2)of this section, reserve samples from representative sample\nlots or batches selected by acceptable statistical procedures shall be examined visually at least once a","book":"21_CFR_Part_211"}
{"chunk":"year for evidence of deterioration unless visual examination would affect the integrity of the reserve\nsample. Any evidence of reserve sample deterioration shall be investigated in accordance with\u00a7 211.192.\nThe results of the examination shall be recorded and maintained with other stability data on the drug","book":"21_CFR_Part_211"}
{"chunk":"product. Reserve samples of compressed medical gases need not be retained. The retention time is as\nfollows:\n(1) For a drug product other than those described inparagraphs (b) (2)and(3)of this section, the\nreserve sample shall be retained for 1 year after the expiration date of the drug product.","book":"21_CFR_Part_211"}
{"chunk":"For a radioactive drug product, except for nonradioactive reagent kits, the reserve sample shall be\nretained for:\n(i) Three months after the expiration date of the drug product if the expiration dating period of the\ndrug product is 30 days or less; or","book":"21_CFR_Part_211"}
{"chunk":"(ii) Six months after the expiration date of the drug product if the expiration dating period of the\ndrug product is more than 30 days.\nFor an OTC drug product that is exempt for bearing an expiration date under\u00a7 211.137, the reserve\nsample must be retained for 3 years after the lot or batch of drug product is distributed.","book":"21_CFR_Part_211"}
{"chunk":"[48 FR 13025, Mar. 29, 1983, as amended at 60 FR 4091, Jan. 20, 1995]\n21 CFR 211.170(b)(3) (enhanced display) (2) (3) page 23 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.173\n\u00a7 211.173 Laboratory animals.","book":"21_CFR_Part_211"}
{"chunk":"Animals used in testing components, in-process materials, or drug products for compliance with established\nspecifications shall be maintained and controlled in a manner that assures their suitability for their intended use.\nThey shall be identified, and adequate records shall be maintained showing the history of their use.","book":"21_CFR_Part_211"}
{"chunk":"\u00a7 211.176 Penicillin contamination.\nIf a reasonable possibility exists that a non-penicillin drug product has been exposed to cross-contamination with\npenicillin, the non-penicillin drug product shall be tested for the presence of penicillin. Such drug product shall not","book":"21_CFR_Part_211"}
{"chunk":"be marketed if detectable levels are found when tested according to procedures specified in \u2018Procedures for\nDetecting and Measuring Penicillin Contamination in Drugs,\u2019 which is incorporated by reference. Copies are\navailable from the Division of Research and Testing (HFD-470), Center for Drug Evaluation and Research, Food and","book":"21_CFR_Part_211"}
{"chunk":"Drug Administration, 5001 Campus Dr., College Park, MD 20740, or available for inspection at the National Archives\nand Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030,\nor go to:http:\/\/www.archives.gov\/federal_register\/code_of_federal_regulations\/ibr_locations.html.","book":"21_CFR_Part_211"}
{"chunk":"[43 FR 45077, Sept. 29, 1978, as amended at 47 FR 9396, Mar. 5, 1982; 50 FR 8996, Mar. 6, 1985; 55 FR 11577, Mar. 29, 1990; 66\n(b) FR 56035, Nov. 6, 2001; 69 FR 18803, Apr. 9, 2004; 81 FR 49897, July 29, 2016]\nSubpart J\u2014Records and Reports\n\u00a7 211.180 General requirements.","book":"21_CFR_Part_211"}
{"chunk":"(a) Any production, control, or distribution record that is required to be maintained in compliance with this\npart and is specifically associated with a batch of a drug product shall be retained for at least 1 year after\nthe expiration date of the batch or, in the case of certain OTC drug products lacking expiration dating","book":"21_CFR_Part_211"}
{"chunk":"because they meet the criteria for exemption under\u00a7 211.137,3years after distribution of the batch.\nRecords shall be maintained for all components, drug product containers, closures, and labeling for at\nleast 1 year after the expiration date or, in the case of certain OTC drug products lacking expiration dating","book":"21_CFR_Part_211"}
{"chunk":"because they meet the criteria for exemption under\u00a7 211.137,3years after distribution of the last lot of\ndrug product incorporating the component or using the container, closure, or labeling.\nAll records required under this part, or copies of such records, shall be readily available for authorized","book":"21_CFR_Part_211"}
{"chunk":"inspection during the retention period at the establishment where the activities described in such records\noccurred. These records or copies thereof shall be subject to photocopying or other means of\nreproduction as part of such inspection. Records that can be immediately retrieved from another location","book":"21_CFR_Part_211"}
{"chunk":"by computer or other electronic means shall be considered as meeting the requirements of this\nparagraph.\nRecords required under this part may be retained either as original records or as true copies such as\nphotocopies, microfilm, microfiche, or other accurate reproductions of the original records. Where","book":"21_CFR_Part_211"}
{"chunk":"reduction techniques, such as microfilming, are used, suitable reader and photocopying equipment shall\nbe readily available.\nWritten records required by this part shall be maintained so that data therein can be used for evaluating, at\nleast annually, the quality standards of each drug product to determine the need for changes in drug","book":"21_CFR_Part_211"}
{"chunk":"product specifications or manufacturing or control procedures. Written procedures shall be established\nand followed for such evaluations and shall include provisions for:\n(c) (d) (e) 21 CFR 211.180(e) (enhanced display) page 24 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)","book":"21_CFR_Part_211"}
{"chunk":"Current Good Manufacturing Practice for Finished Pharmaceuticals (1) (2) 21 CFR 211.180(e)(1)\nA review of a representative number of batches, whether approved or rejected, and, where applicable,\nrecords associated with the batch.\nA review of complaints, recalls, returned or salvaged drug products, and investigations conducted","book":"21_CFR_Part_211"}
{"chunk":"under\u00a7 211.192for each drug product.\n(f) Procedures shall be established to assure that the responsible officials of the firm, if they are not\npersonally involved in or immediately aware of such actions, are notified in writing of any investigations\nconducted under \u00a7\u00a7 211.198, 211.204, or 211.208 of these regulations, any recalls, reports of","book":"21_CFR_Part_211"}
{"chunk":"inspectional observations issued by the Food and Drug Administration, or any regulatory actions relating\nto good manufacturing practices brought by the Food and Drug Administration.\n[43 FR 45077, Sept. 29, 1978, as amended at 60 FR 4091, Jan. 20, 1995]\n\u00a7 211.182 Equipment cleaning and use log.","book":"21_CFR_Part_211"}
{"chunk":"A written record of major equipment cleaning, maintenance (except routine maintenance such as lubrication and\nadjustments), and use shall be included in individual equipment logs that show the date, time, product, and lot\nnumber of each batch processed. If equipment is dedicated to manufacture of one product, then individual","book":"21_CFR_Part_211"}
{"chunk":"equipment logs are not required, provided that lots or batches of such product follow in numerical order and are\nmanufactured in numerical sequence. In cases where dedicated equipment is employed, the records of cleaning,\nmaintenance, and use shall be part of the batch record. The persons performing and double-checking the cleaning","book":"21_CFR_Part_211"}
{"chunk":"and maintenance (or, if the cleaning and maintenance is performed using automated equipment under\u00a7 211.68,\njust the person verifying the cleaning and maintenance done by the automated equipment) shall date and sign or\ninitial the log indicating that the work was performed. Entries in the log shall be in chronological order.","book":"21_CFR_Part_211"}
{"chunk":"[73 FR 51933, Sept. 8, 2008]\n\u00a7 211.184 Component, drug product container, closure, and labeling records.\nThese records shall include the following:\n(a) The identity and quantity of each shipment of each lot of components, drug product containers, closures,","book":"21_CFR_Part_211"}
{"chunk":"and labeling; the name of the supplier; the supplier's lot number(s) if known; the receiving code as\nspecified in\u00a7 211.80; and the date of receipt. The name and location of the prime manufacturer, if\n(b) different from the supplier, shall be listed if known.","book":"21_CFR_Part_211"}
{"chunk":"The results of any test or examination performed (including those performed as required by\u00a7 211.82(a),\u00a7\n211.84(d), or\u00a7 211.122(a)) and the conclusions derived therefrom.\n(c) (d) An individual inventory record of each component, drug product container, and closure and, for each","book":"21_CFR_Part_211"}
{"chunk":"component, a reconciliation of the use of each lot of such component. The inventory record shall contain\nsufficient information to allow determination of any batch or lot of drug product associated with the use\nof each component, drug product container, and closure.","book":"21_CFR_Part_211"}
{"chunk":"Documentation of the examination and review of labels and labeling for conformity with established\nspecifications in accord with\u00a7\u00a7 211.122(c)and211.130(c).\n(e) The disposition of rejected components, drug product containers, closure, and labeling.\n21 CFR 211.184(e) (enhanced display) page 25 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)","book":"21_CFR_Part_211"}
{"chunk":"Current Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.186\n\u00a7 211.186 Master production and control records.\n(a) To assure uniformity from batch to batch, master production and control records for each drug product,\nincluding each batch size thereof, shall be prepared, dated, and signed (full signature, handwritten) by one","book":"21_CFR_Part_211"}
{"chunk":"person and independently checked, dated, and signed by a second person. The preparation of master\nproduction and control records shall be described in a written procedure and such written procedure shall\nbe followed.\n(b) Master production and control records shall include:","book":"21_CFR_Part_211"}
{"chunk":"(1) The name and strength of the product and a description of the dosage form;\n(2) The name and weight or measure of each active ingredient per dosage unit or per unit of weight or\nmeasure of the drug product, and a statement of the total weight or measure of any dosage unit;","book":"21_CFR_Part_211"}
{"chunk":"(3) A complete list of components designated by names or codes sufficiently specific to indicate any\nspecial quality characteristic;\n(4) An accurate statement of the weight or measure of each component, using the same weight system\n(metric, avoirdupois, or apothecary) for each component. Reasonable variations may be permitted,","book":"21_CFR_Part_211"}
{"chunk":"however, in the amount of components necessary for the preparation in the dosage form, provided\nthey are justified in the master production and control records;\n(5) A statement concerning any calculated excess of component;\n(6) A statement of theoretical weight or measure at appropriate phases of processing;","book":"21_CFR_Part_211"}
{"chunk":"(7) A statement of theoretical yield, including the maximum and minimum percentages of theoretical\nyield beyond which investigation according to\u00a7 211.192is required;\n(8) A description of the drug product containers, closures, and packaging materials, including a","book":"21_CFR_Part_211"}
{"chunk":"specimen or copy of each label and all other labeling signed and dated by the person or persons\nresponsible for approval of such labeling;\n(9) Complete manufacturing and control instructions, sampling and testing procedures, specifications,\nspecial notations, and precautions to be followed.\n\u00a7 211.188 Batch production and control records.","book":"21_CFR_Part_211"}
{"chunk":"Batch production and control records shall be prepared for each batch of drug product produced and shall include\ncomplete information relating to the production and control of each batch. These records shall include:\n(a) An accurate reproduction of the appropriate master production or control record, checked for accuracy,\ndated, and signed;","book":"21_CFR_Part_211"}
{"chunk":"dated, and signed;\n(b) Documentation that each significant step in the manufacture, processing, packing, or holding of the batch\nwas accomplished, including:\n(1) Dates;\n(2) Identity of individual major equipment and lines used;\n(3) Specific identification of each batch of component or in-process material used;","book":"21_CFR_Part_211"}
{"chunk":"(4) Weights and measures of components used in the course of processing;\n21 CFR 211.188(b)(4) (enhanced display) page 26 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals (5) In-process and laboratory control results;","book":"21_CFR_Part_211"}
{"chunk":"(6) Inspection of the packaging and labeling area before and after use;\n(7) A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate\nphases of processing;\n(8) Complete labeling control records, including specimens or copies of all labeling used;\n(9) Description of drug product containers and closures;","book":"21_CFR_Part_211"}
{"chunk":"(10) Any sampling performed;\n(11) Identification of the persons performing and directly supervising or checking each significant step in\nthe operation, or if a significant step in the operation is performed by automated equipment under\u00a7\n211.68, the identification of the person checking the significant step performed by the automated\nequipment.","book":"21_CFR_Part_211"}
{"chunk":"equipment.\n(12) Any investigation made according to\u00a7 211.192.\n(13) Results of examinations made in accordance with\u00a7 211.134.\n[43 FR 45077, Sept. 29, 1978, as amended at 73 FR 51933, Sept. 8, 2008]\n\u00a7 211.192 Production record review.\nAll drug product production and control records, including those for packaging and labeling, shall be reviewed and","book":"21_CFR_Part_211"}
{"chunk":"approved by the quality control unit to determine compliance with all established, approved written procedures\nbefore a batch is released or distributed. Any unexplained discrepancy (including a percentage of theoretical yield\nexceeding the maximum or minimum percentages established in master production and control records) or the","book":"21_CFR_Part_211"}
{"chunk":"failure of a batch or any of its components to meet any of its specifications shall be thoroughly investigated,\nwhether or not the batch has already been distributed. The investigation shall extend to other batches of the same\ndrug product and other drug products that may have been associated with the specific failure or discrepancy. A","book":"21_CFR_Part_211"}
{"chunk":"written record of the investigation shall be made and shall include the conclusions and followup.\n\u00a7 211.194 Laboratory records.\n(a) Laboratory records shall include complete data derived from all tests necessary to assure compliance\nwith established specifications and standards, including examinations and assays, as follows:","book":"21_CFR_Part_211"}
{"chunk":"(1) A description of the sample received for testing with identification of source (that is, location from\nwhere sample was obtained), quantity, lot number or other distinctive code, date sample was taken,\nand date sample was received for testing.\nA statement of each method used in the testing of the sample. The statement shall indicate the","book":"21_CFR_Part_211"}
{"chunk":"location of data that establish that the methods used in the testing of the sample meet proper\nstandards of accuracy and reliability as applied to the product tested. (If the method employed is in\nthe current revision of the United States Pharmacopeia, National Formulary, AOAC INTERNATIONAL,","book":"21_CFR_Part_211"}
{"chunk":"Book of Methods,[1]or in other recognized standard references, or is detailed in an approved new\ndrug application and the referenced method is not modified, a statement indicating the method and\nreference will suffice). The suitability of all testing methods used shall be verified under actual\nconditions of use.\n21 CFR 211.188(b)(5)","book":"21_CFR_Part_211"}
{"chunk":"(2) 21 CFR 211.194(a)(2) (enhanced display) page 27 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.194(a)(3)\n(3) (4) (5) (6) (7) (8) A statement of the weight or measure of sample used for each test, where appropriate.","book":"21_CFR_Part_211"}
{"chunk":"A complete record of all data secured in the course of each test, including all graphs, charts, and\nspectra from laboratory instrumentation, properly identified to show the specific component, drug\nproduct container, closure, in-process material, or drug product, and lot tested.","book":"21_CFR_Part_211"}
{"chunk":"A record of all calculations performed in connection with the test, including units of measure,\nconversion factors, and equivalency factors.\nA statement of the results of tests and how the results compare with established standards of\nidentity, strength, quality, and purity for the component, drug product container, closure, in-process","book":"21_CFR_Part_211"}
{"chunk":"material, or drug product tested.\nThe initials or signature of the person who performs each test and the date(s) the tests were\nperformed.\nThe initials or signature of a second person showing that the original records have been reviewed for\naccuracy, completeness, and compliance with established standards.","book":"21_CFR_Part_211"}
{"chunk":"Complete records shall be maintained of any modification of an established method employed in testing.\nSuch records shall include the reason for the modification and data to verify that the modification\nproduced results that are at least as accurate and reliable for the material being tested as the established\nmethod.","book":"21_CFR_Part_211"}
{"chunk":"method.\nComplete records shall be maintained of any testing and standardization of laboratory reference\nstandards, reagents, and standard solutions.\nComplete records shall be maintained of the periodic calibration of laboratory instruments, apparatus,\ngauges, and recording devices required by\u00a7 211.160(b)(4).","book":"21_CFR_Part_211"}
{"chunk":"Complete records shall be maintained of all stability testing performed in accordance with\u00a7 211.166.\n[43 FR 45077, Sept. 29, 1978, as amended at 55 FR 11577, Mar. 29, 1990; 65 FR 18889, Apr. 10, 2000; 70 FR 40880, July 15, 2005;\n70 FR 67651, Nov. 8, 2005]\n(b) (c) (d) (e) \u00a7 211.196 Distribution records.","book":"21_CFR_Part_211"}
{"chunk":"Link to an amendment published at89 FR 51770, June 18, 2024.\nDistribution records shall contain the name and strength of the product and description of the dosage form, name\nand address of the consignee, date and quantity shipped, and lot or control number of the drug product. For","book":"21_CFR_Part_211"}
{"chunk":"compressed medical gas products, distribution records are not required to contain lot or control numbers.\n(Approved by the Office of Management and Budget under control number 0910-0139)\n[49 FR 9865, Mar. 16, 1984]\n[1]Copies may be obtained from: AOAC INTERNATIONAL, 481 North Frederick Ave., suite 500, Gaithersburg,\nMD 20877.","book":"21_CFR_Part_211"}
{"chunk":"MD 20877.\n21 CFR 211.196 (enhanced display) page 28 of 30\n21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.198\n\u00a7 211.198 Complaint files.\n(a) Written procedures describing the handling of all written and oral complaints regarding a drug product","book":"21_CFR_Part_211"}
{"chunk":"shall be established and followed. Such procedures shall include provisions for review by the quality\ncontrol unit, of any complaint involving the possible failure of a drug product to meet any of its\nspecifications and, for such drug products, a determination as to the need for an investigation in","book":"21_CFR_Part_211"}
{"chunk":"accordance with\u00a7 211.192. Such procedures shall include provisions for review to determine whether the\ncomplaint represents a serious and unexpected adverse drug experience which is required to be reported\nto the Food and Drug Administration in accordance with\u00a7\u00a7 310.305and514.80 of this chapter.","book":"21_CFR_Part_211"}
{"chunk":"(b) A written record of each complaint shall be maintained in a file designated for drug product complaints.\nThe file regarding such drug product complaints shall be maintained at the establishment where the drug\nproduct involved was manufactured, processed, or packed, or such file may be maintained at another","book":"21_CFR_Part_211"}
{"chunk":"facility if the written records in such files are readily available for inspection at that other facility. Written\nrecords involving a drug product shall be maintained until at least 1 year after the expiration date of the\ndrug product, or 1 year after the date that the complaint was received, whichever is longer. In the case of","book":"21_CFR_Part_211"}
{"chunk":"certain OTC drug products lacking expiration dating because they meet the criteria for exemption under\u00a7\n211.137, such written records shall be maintained for 3 years after distribution of the drug product.\n(1) (2) (3) The written record shall include the following information, where known: the name and strength of","book":"21_CFR_Part_211"}
{"chunk":"the drug product, lot number, name of complainant, nature of complaint, and reply to complainant.\nWhere an investigation under\u00a7 211.192is conducted, the written record shall include the findings of\nthe investigation and followup. The record or copy of the record of the investigation shall be","book":"21_CFR_Part_211"}
{"chunk":"maintained at the establishment where the investigation occurred in accordance with\u00a7 211.180(c).\nWhere an investigation under\u00a7 211.192is not conducted, the written record shall include the reason\nthat an investigation was found not to be necessary and the name of the responsible person making\nsuch a determination.","book":"21_CFR_Part_211"}
{"chunk":"[43 FR 45077, Sept. 29, 1978, as amended at 51 FR 24479, July 3, 1986; 68 FR 15364, Mar. 31, 2003]\nSubpart K\u2014Returned and Salvaged Drug Products\n\u00a7 211.204 Returned drug products.\nReturned drug products shall be identified as such and held. If the conditions under which returned drug products","book":"21_CFR_Part_211"}
{"chunk":"have been held, stored, or shipped before or during their return, or if the condition of the drug product, its container,\ncarton, or labeling, as a result of storage or shipping, casts doubt on the safety, identity, strength, quality or purity of","book":"21_CFR_Part_211"}
{"chunk":"the drug product, the returned drug product shall be destroyed unless examination, testing, or other investigations\nprove the drug product meets appropriate standards of safety, identity, strength, quality, or purity. A drug product\nmay be reprocessed provided the subsequent drug product meets appropriate standards, specifications, and","book":"21_CFR_Part_211"}
{"chunk":"characteristics. Records of returned drug products shall be maintained and shall include the name and label\npotency of the drug product dosage form, lot number (or control number or batch number), reason for the return,\nquantity returned, date of disposition, and ultimate disposition of the returned drug product. If the reason for a drug","book":"21_CFR_Part_211"}
{"chunk":"product being returned implicates associated batches, an appropriate investigation shall be conducted in\naccordance with the requirements of\u00a7 211.192. Procedures for the holding, testing, and reprocessing of returned\ndrug products shall be in writing and shall be followed.\n21 CFR 211.204 (enhanced display) page 29 of 30","book":"21_CFR_Part_211"}
{"chunk":"21 CFR Part 211 (up to date as of 7\/24\/2025)\nCurrent Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR 211.208\n\u00a7 211.208 Drug product salvaging.\nDrug products that have been subjected to improper storage conditions including extremes in temperature,","book":"21_CFR_Part_211"}
{"chunk":"humidity, smoke, fumes, pressure, age, or radiation due to natural disasters, fires, accidents, or equipment failures\nshall not be salvaged and returned to the marketplace. Whenever there is a question whether drug products have\nbeen subjected to such conditions, salvaging operations may be conducted only if there is (a) evidence from","book":"21_CFR_Part_211"}
{"chunk":"laboratory tests and assays (including animal feeding studies where applicable) that the drug products meet all\napplicable standards of identity, strength, quality, and purity and (b) evidence from inspection of the premises that\nthe drug products and their associated packaging were not subjected to improper storage conditions as a result of","book":"21_CFR_Part_211"}
{"chunk":"the disaster or accident. Organoleptic examinations shall be acceptable only as supplemental evidence that the\ndrug products meet appropriate standards of identity, strength, quality, and purity. Records including name, lot\nnumber, and disposition shall be maintained for drug products subject to this section.","book":"21_CFR_Part_211"}
{"chunk":"21 CFR 211.208 (enhanced display) page 30 of 30","book":"21_CFR_Part_211"}
